癌症纳米医学：从靶向递送至联合治疗
Cancer nanomedicine: from targeted delivery to combination therapy.
作者信息
Xu Xiaoyang, Ho William, Zhang Xueqing, Bertrand Nicolas, Farokhzad Omid
机构信息
Laboratory of Nanomedicine and Biomaterials, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Chemical, Biological and Pharmaceutical Engineering, New Jersey Institute of Technology, Newark, NJ 07102, USA.
Laboratory of Nanomedicine and Biomaterials, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
出版信息
Trends Mol Med. 2015 Apr;21(4):223-32. doi: 10.1016/j.molmed.2015.01.001. Epub 2015 Feb 2.
The advent of nanomedicine marks an unparalleled opportunity to advance the treatment of various diseases, including cancer. The unique properties of nanoparticles (NPs), such as large surface-to-volume ratio, small size, the ability to encapsulate various drugs, and tunable surface chemistry, give them many advantages over their bulk counterparts. This includes multivalent surface modification with targeting ligands, efficient navigation of the complex in vivo environment, increased intracellular trafficking, and sustained release of drug payload. These advantages make NPs a mode of treatment potentially superior to conventional cancer therapies. This review highlights the most recent developments in cancer treatment using NPs as drug delivery vehicles, including promising opportunities in targeted and combination therapy.
纳米医学的出现为推进包括癌症在内的各种疾病的治疗带来了前所未有的机遇。纳米颗粒（NPs）的独特性质，如大的表面积与体积比、小尺寸、封装各种药物的能力以及可调节的表面化学性质，使其相对于其块状对应物具有许多优势。这包括用靶向配体进行多价表面修饰、在体内复杂环境中有效导航、增加细胞内运输以及药物载荷的持续释放。这些优势使纳米颗粒成为一种可能优于传统癌症治疗方法的治疗方式。本综述重点介绍了使用纳米颗粒作为药物递送载体在癌症治疗方面的最新进展，包括靶向治疗和联合治疗中的潜在机遇。
Zotero 插件